Indicated for:

Angina Pectoris:

• The long-term management of patients with angina pectoris.

Hypertension:

• The management of hypertension, to lower blood pressure. CORGARD (nadolol) may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken.

Nadolol is contraindicated in bronchial asthma, sinus bradycardia and greater than first degree conduction block, cardiogenic shock, and overt cardiac failure.

Patients with bronchospastic diseases should in general not receive beta-blockers. Nadolol should be administered with caution since it may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta2 receptors.

In patients without a history of heart failure, continued use of beta-blockers can, in some cases, lead to cardiac failure. Therefore, at the first sign or symptom of heart failure, the patient should be digitalized and/or treated with diuretics, and the response observed closely, or nadolol should be discontinued (gradually, if possible).

Nadolol should be used with caution in patients with impaired renal function.

Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures.

Beta-adrenergic blockade may prevent the appearance of premonitory signs and symptoms (e.g., tachycardia and blood pressure changes) of acute hypoglycemia. This is especially important with labile diabetics. Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs.

Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm.

Use with anesthetics: exaggeration of the hypotension induced by general anesthetics.

Use with antidiabetic drugs (oral agents and insulin): hypoglycemia or hyperglycemia; adjust dosage of antidiabetic drug accordingly.

Use with catecholamine-depleting drugs (e.g., reserpine): additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension).

Use with digitalis glycosides: Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Neonates whose mothers are receiving nadolol at parturition have exhibited bradycardia, hypoglycemia, and associated symptoms.

Nadolol is excreted in human milk. Because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the importance of CORGARD (nadolol) to the mother.

GoToSource

• Use in patients under the age of 18. GoToSource

• Dosage greater than 240 mg per day for angina pectoris and dosage greater than 320 mg per day for hypertension. GoToSource

• Prophylactic treatment for migraines. GoToSource

• Prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. GoToSource

• Prophylaxis of first variceal bleeding. GoToSource

• Performance anxiety. GoToSource

Thrombocytopenia (low blood platelet count). GoToSource

Bradycardia (slow heart rate). GoToSource 

Infiltrative dermatitis and alopecia (hair loss). GoToSource

Hypertriglyceridemia (elevated triglyceride levels) and pancreatitis (inflammation of pancreas). GoToSource

Hypotension (low blood pressure), depression, visual disturbances, hallucinations, short term memory loss, peripheral vascular insufficiency, impotence, decreased libido and weight gain. GoToSource

Increased blood glucose. GoToSource

Bronchospasm. GoToSource

Lawsuit filed for aggravation of congestive heart failure.